Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

Lack of consensus for first‐line marginal zone lymphoma (MZL) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first‐l...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Becnel, Melody R., Nastoupil, Loretta J., Samaniego, Felipe, Davis, Richard E., You, M. J., Green, Michael, Hagemeister, Fredrick B., Fanale, Michelle A., Fayad, Luis E., Westin, Jason R., Wang, Michael, Oki, Yasuhiro, Forbes, Sheryl G., Feng, Lei, Neelapu, Sattva S., Fowler, Nathan H.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Haematological Malignancy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6619290/
https://ncbi.nlm.nih.gov/pubmed/30919940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15843
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars